↓ Skip to main content

Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease

Overview of attention for article published in Molecular Neurodegeneration, January 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)
  • Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

news
1 news outlet
twitter
1 tweeter
patent
1 patent
facebook
2 Facebook pages
googleplus
1 Google+ user

Citations

dimensions_citation
110 Dimensions

Readers on

mendeley
184 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
Published in
Molecular Neurodegeneration, January 2016
DOI 10.1186/s13024-016-0072-9
Pubmed ID
Authors

Nour K. Majbour, Nishant N. Vaikath, Karin D. van Dijk, Mustafa T. Ardah, Shiji Varghese, Louise B. Vesterager, Liliana P. Montezinho, Stephen Poole, Bared Safieh-Garabedian, Takahiko Tokuda, Charlotte E. Teunissen, Henk W. Berendse, Wilma D. J. van de Berg, Omar M. A. El-Agnaf

Abstract

Despite decades of intensive research, to date, there is no accepted diagnosis for Parkinson's disease (PD) based on biochemical analysis of blood or CSF. However, neurodegeneration in the brains of PD patients begins several years before the manifestation of the clinical symptoms, pointing to serious flaw/limitations in this approach. To explore the potential use of alpha-synuclein (α-syn) species as candidate biomarkers for PD, we generated specific antibodies directed against wide array of α-syn species, namely total-, oligomeric- and phosphorylated-Ser129-α-syn (t-, o- and p-S129-α-syn). Next we sought to employ our antibodies to develop highly specific ELISA assays to quantify α-syn species in biological samples. Finally we verified the usefulness of our assays in CSF samples from 46 PD patients and 48 age-matched healthy controls. We also assessed the discriminating power of combining multiple CSF α-syn species with classical Alzheimer's disease biomarkers. The combination of CSF o-/t-α-syn, p-S129-α-syn and p-tau provided the best fitting predictive model for discriminating PD patients from controls. Moreover, CSF o-α-syn levels correlated significantly with the severity of PD motor symptoms (r = -0.37). Our new ELISA assays can serve as research tools to address the unmet need for reliable CSF biomarkers for PD and related disorders.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 184 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 1%
Unknown 182 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 36 20%
Student > Ph. D. Student 33 18%
Student > Master 29 16%
Student > Bachelor 17 9%
Student > Doctoral Student 11 6%
Other 28 15%
Unknown 30 16%
Readers by discipline Count As %
Neuroscience 39 21%
Agricultural and Biological Sciences 31 17%
Biochemistry, Genetics and Molecular Biology 23 13%
Medicine and Dentistry 16 9%
Pharmacology, Toxicology and Pharmaceutical Science 9 5%
Other 21 11%
Unknown 45 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 November 2018.
All research outputs
#1,163,251
of 13,855,981 outputs
Outputs from Molecular Neurodegeneration
#74
of 581 outputs
Outputs of similar age
#33,626
of 337,142 outputs
Outputs of similar age from Molecular Neurodegeneration
#2
of 9 outputs
Altmetric has tracked 13,855,981 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 581 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.8. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 337,142 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 7 of them.